Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$13.3B
48M shares
52-week range
$144.26 – $303.31
81% from low
Sector
SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH
Exchange
NYSE
CS
P/S (TTM)
3.3
EV / FCF (TTM)
43.4
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provide in vitro (nonanimal) testing products, biologics testing services, and avian vaccine services.
www.criver.comNo one on the platform currently holds CRL.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2025-12-31 | 10,200 | $2.0M |
| Bridgewater Associatesas of 2026-03-31 | 6,835 | $1.2M |
No one on the platform has traded CRL yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | — | — | — | |||
| Rev. Growth % | -0.9% | 6.5% | ||||
| Profit Margin % | -3.6% | 6.3% | 7.9% | |||
| Free Cash Flow Margin % | 12.9% | 11.3% | 12.3% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is +2.8% on the P/E track.
At today's price, your expected annual return is +7.8% on the P/E track.
At today's price, your expected annual return is +12.2% on the P/E track.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.9B | -2.5% | $11.32 | $11.12–$11.46 | 24.1× | 10 |
| 2027 | $4.0B | +2.1% | $12.73 | $12.04–$13.15 | 21.4× | 10 |
| 2028 | $4.2B | +4.8% | $14.18 | $8.83–$17.88 | 19.3× | 5 |
| 2029 | $4.5B | +7.5% | $16.04 | $15.80–$16.39 | 17.0× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $2.74 | $3.02 | +10.2% |
| 2026-05-07 | $1.96 | $2.06 | +5.1% |
| 2026-02-18 | $2.33 | $2.39 | +2.6% |
| 2025-11-05 | $2.32 | $2.43 | +4.7% |
| 2025-08-06 | $2.50 | $3.12 | +24.8% |
| 2025-05-07 | $2.06 | $2.34 | +13.6% |
| 2025-02-19 | $2.50 | $2.66 | +6.4% |
| 2024-11-06 | $2.42 |
| $2.59 |
| +7.0% |
| $7.4B |
| — |
| DVADaVita Inc. | $189.32 | +4.28% | $12.2B | — |
| PENPenumbra, Inc. | $319.86 | +0.67% | $12.6B | — |
Source: Financial Modeling Prep · peers by sector/industry
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
$CRL undiscovered breakout with 924 watchers
View on StockTwits ↗
$MRNA $CRL Kinda sucks… checked out MRNA on Monday but ended up picking CRL instead. Opened a position there and missed today’s MRNA move.
View on StockTwits ↗
$CRCL engulfer off the 10/50d $CRL crankin ...unrelated or are they?
View on StockTwits ↗
$CRL Mizuho raises target price to $264 from $230 TD Cowen raises target price to $300 from $235
View on StockTwits ↗
$CRL: Charles River Laboratories upgraded to Overweight from Neutral at JPMorgan, tgt $310 https://www.briefing.com/calendars/updown?Filter=All&utm_campaign=updown&utm_medium=social&utm_source=st&utm_content=link
View on StockTwits ↗
Top Gainers for August 5, 2026: $DT +13.2% to $51.76 — Software Observability Surprises to the Upside $ANET +10.3% — $3.3 Billion Q3 Revenue Guidance Is the Tell $CRL +11% to $260 — Pharma Enabler Has a Strong Quarter $FUBO +6.28% to $10.15 — Profitability Story Wins Despite Revenue Slip $REPL +1.01% to $12.04 — Biotech Holds as Sector Rotates https://truthsandnews.com/markets/top-10-stock-gainers-today-aug-5-2026-apps-shop-blmn
View on StockTwits ↗
https://www.marketbeat.com/earnings/reports/2026-8-5-charles-river-laboratories-international-inc-stock/ $CRL Charles River Laboratories I
View on StockTwits ↗
$CRL (+8.1% pre) Charles River Labs stock climbs 8% on Q2 beat, raised guidance https://ooc.bz/l/109970
View on StockTwits ↗
$CRL Positive (82%): CRL’s stock is likely to face upward pressure because higher 2026 guidance supports stronger forward earnings and cash-flow expectations, although falling quarterly earnings and revenue could limit the gain. Full AI impact map, source, and watch-next details: https://nimpact.tech/newsimpact/news/1466346ecb0fc797?utm_source=stocktwits&utm_medium=story_url
View on StockTwits ↗
$CRL Q2 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.03 down -102.83% YoY • Reported revenue of $1B down -2.72% YoY • Charles River Laboratories is increasing its 2026 revenue and non-GAAP earnings per share guidance, reflecting operational outperformance, while reducing GAAP earnings per share guidance due to net loss from divestitures.
View on StockTwits ↗
$CRL Opportunity Morgan Stanley raises PT to $260.00 from $220.00
View on StockTwits ↗
$CDXS This is interesting, ST Pharm partnering with Vigen, owned by Charles River Labratories $CRL , for CDMO manufacturing in the US! My question is, will Codexis be involved in this partnership potentially? https://www.asiae.co.kr/en/article/bio-health/2026061710572918087
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.